The objectives of this symposium were to improve attendees’ knowledge on ADT, including the different therapeutic options ...

A new study sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center ... following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing ...

Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

Immunotherapy Shows Promise for Men With Specific Types of Prostate ... recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key ...

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. A supplemental new drug application has ...

A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

Survival after moderate HFRT in patients with high-risk prostate cancer was a secondary outcome of the randomized phase 3 Prostate Cancer Study 5 trial.

Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada ... a combination regimen with androgen deprivation therapy (ADT) caused a ...

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center ... following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing ...